KYTX Stock Analysis: Kyverna Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 513m USD | 12M Return: 279.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.61M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 2.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is a late-stage clinical biopharmaceutical company developing cell therapies for autoimmune diseases. The company is headquartered in Emeryville, California, was incorporated in 2018, and completed its IPO in February 2024.
The companys lead product candidate is KYV-101, an autologous CD19 CAR T-cell therapy being studied in stiff person syndrome, myasthenia gravis, and other autoimmune indications. The pipeline also includes KYV-102, an autologous CD19 CAR T-cell candidate using a whole blood rapid manufacturing process, and KYV-201, an allogeneic CD19 CAR T-cell candidate.
Kyverna holds a license and collaboration agreement with Intellia Therapeutics to research and develop an allogeneic CD19-directed CAR cell therapy product, providing a partnership-driven path in the gene-editing and cell therapy space. The company was formerly known as BAIT Therapeutics, Inc. before adopting its current name in October 2019.
As a clinical-stage biopharmaceutical company, Kyverna does not yet generate commercial product revenue and is dependent on capital markets and partnerships to fund its research and development activities. The autoimmune disease cell therapy sector remains an emerging field applying oncology-style modalities such as CAR T-cell technology to non-cancer conditions, including rare and severe autoimmune disorders.
- KYV-101 Phase 2 data readout in stiff person syndrome
- FDA fast track designation decision for KYV-101 in myasthenia gravis
- Cash runway shortens as quarterly R&D burn accelerates
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.59 > 0.02 and ΔFCF/TA -6.84 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.59 > 3% & CFO -150.4m > Net Income -156.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.4m) vs 12m ago 39.84% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.78%; Δ -0.78% > 0%) |
| Interest Coverage Ratio: -137.2 > 6 (EBIT TTM -155.3m / Interest Expense TTM 1.13m) |
| A: 0.83 (Total Current Assets 241.7m - Total Current Liabilities 29.7m) / Total Assets 257.0m |
| B: -1.81 (Retained Earnings -464.6m / Total Assets 257.0m) |
| C: -0.60 (EBIT TTM -155.3m / Avg Total Assets 258.8m) |
| D: 3.18 (Book Value of Equity 195.6m / Total Liabilities 61.4m) |
| Altman-Z'' = -1.17 = CCC |
As of July 08, 2026, the stock is trading at USD 9.68 with a total of 1,197,431 shares traded. Over the past week, the price has changed by +10.25%, over one month by +25.55%, over three months by +3.75% and over the past year by +279.61%.
Current recommended Stop Loss: 8.90 (which is 8.1% or 1.4 ATR below the current price).
Kyverna Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy KYTX.
- StrongBuy: 3
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30.4 | 214% |
P/S = 3513.3428
P/B = 2.6266
Revenue TTM = 0.0 USD
EBIT TTM = -155.3m USD
EBITDA TTM = -153.6m USD
Long Term Debt = 24.8m USD (from longTermDebt, last quarter)
Short Term Debt = 1.99m USD (from shortTermDebt, last quarter)
Debt = 42.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.94m
Net Debt = -193.7m USD (calculated: Debt 42.7m - CCE 236.4m)
Enterprise Value = 319.4m USD (513.1m + Debt 42.7m - CCE 236.4m)
Interest Coverage Ratio = -137.2 (Ebit TTM -155.3m / Interest Expense TTM 1.13m)
EV/FCF = -2.12x (Enterprise Value 319.4m / FCF TTM -151.0m)
FCF Yield = -47.28% (FCF TTM -151.0m / Enterprise Value 319.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.65m) / Revenue TTM)
Tobins Q-Ratio = 1.24 (Enterprise Value 319.4m / Total Assets 257.0m)
Interest Expense / Debt = 2.65% (Interest Expense 1.13m / Debt 42.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -122.7m (EBIT -155.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.15 (Total Current Assets 241.7m / Total Current Liabilities 29.7m)
Debt / Equity = 0.22 (Debt 42.7m / totalStockholderEquity, last quarter 195.6m)
Debt / EBITDA = 1.26 (negative EBITDA) (Net Debt -193.7m / EBITDA -153.6m)
Debt / FCF = 1.28 (negative FCF - burning cash) (Net Debt -193.7m / FCF TTM -151.0m)
Total Stockholder Equity = 191.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -60.42% (Net Income -156.4m / Total Assets 257.0m)
RoE = -81.87% (Net Income TTM -156.4m / Total Stockholder Equity 191.0m)
RoCE = -71.93% (EBIT -155.3m / Capital Employed (Equity 191.0m + L.T.Debt 24.8m))
RoIC = -53.49% (negative operating profit) (NOPAT -122.7m / Invested Capital 229.3m)
WACC = 12.53% (E(513.1m)/V(555.8m) * Re(13.40%) + D(42.7m)/V(555.8m) * Rd(2.65%) * (1-Tc(0.21)))
Discount Rate = 13.40% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.56 | Cagr: 16.19%
[DCF] Fair Price = unknown (Cash Flow -151.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.87 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.68 | Chg30d=+8.67% | Revisions=+29% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-0.74 | Chg30d=-2.29% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=-2.88 | Chg30d=+1.62% | Revisions=+0% | GrowthEPS=+21.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.95 | Chg30d=-3.70% | Revisions=+0% | GrowthEPS=-2.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +11% (up=9, down=7)